Poolbeg Pharma (LON:POLB) Trading Down 2.5% – Here’s Why

Poolbeg Pharma PLC (LON:POLB)’s share price traded down 2.5% during trading on Tuesday . The stock traded as low as GBX 3.90 and last traded at GBX 3.90. 384,483 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 1,804,502 shares. The stock had previously closed at GBX 4.

Wall Street Analysts Forecast Growth

Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research note on Thursday, November 20th.

Poolbeg Pharma Stock Down 2.5%

The company’s fifty day moving average price is GBX 3.83 and its 200 day moving average price is GBX 3.50. The company has a market capitalization of £27.19 million, a P/E ratio of -3.42 and a beta of 2.11.

Poolbeg Pharma (LON:POLB) last issued its quarterly earnings results on Monday, September 29th. The company reported GBX (0.43) earnings per share (EPS) for the quarter. Research analysts predict that Poolbeg Pharma PLC will post -0.68 earnings per share for the current fiscal year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.